NCT03296800View on ClinicalTrials.gov

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 27, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 6, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Bexagliflozin

Bexagliflozin 20 mg, tablet; qd

DRUG

Probenecid

Probenecid tablets, 500 mg; bid

DRUG

Rifampin

Rifampin, 600 mg (2 x 300 mg capsules); qd

DRUG

Verapamil

Verapamil hydrochloride tablet, 120 mg; qd

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Lead Sponsor

Theracos
All Listed Sponsors
lead

Theracos

INDUSTRY

NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects | Biotech Hunter | Biotech Hunter